3. Custódio G, Parise GA, Kiesel Filho N, et al. Impact of Neonatal Screening and Surveillance for the TP53 R337H Mutation on Early Detection of Childhood Adrenocortical Tumors. J Clin Oncol 2013; 31: 2619-2626.
4. Allolio B, Fassnacht M. Adrenocortical carcinoma, In: Grossman, A.P. Endocrinology Adult and pediatric, The adrenal gland. sixth ed. Philadelphia: Elsevier; 2010, pp. e168.
5. Mauclère-Denost S, Leboulleux S, Borget I, et al. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Eur J Endocrinol 2012; 166: 261–268. https://doi.org/10.1530/EJE-11-0557
6. Zancanella P, Pianovski MA, Oliveira BH, et al. Mitotane Associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma. J Pediatr Hematol Oncol 2006; 28: 513–524. https://doi.org/10.1097/01.mph.0000212965.52759.1c
7. Berruti A, Terzolo M, Pia A, et al. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 1998; 83: 2194-2000.
8. Pereira RM, Michalkiewicz E, Sandrini F, et al. Childhood Adrenocortical Tumors: A Review. Arq Bras Endocrinol Metabol 2004; 48: 651-658.
9. Terzolo M, Pia A, Berruti A, et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 2000; 85: 2234–2238. https://doi.org/10.1210/jcem.85.6.6619
10. Daffara F, De Francia S, Reimondo G, et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 2008; 15: 1043–1053. https://doi.org/10.1677/ERC-08-0103
11. Nelson AA, Woodard G. Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1-dichloroethane (DDD or TDE). Arch Pathol (Chic) 1949; 48: 387–394.
12. Nichols J, Green HD. Effect of DDD Treatment on Metabolic Response of Dogs to ACTH Injection. Am J Physiol 1954; 176: 374–376. https://doi.org/10.1152/ajplegacy.1954.176.3.374
13. Bergenstal DM, Lipsett MB, Moy RH, et al. Regression of adrenal cancer and suppression of adrenal function in men by o,p′-DDD. Trans Assoc Am Physicians 1959; 72: 341.  https://doi.org/10.1016/B978-1-4832-2866-2.50035-0
14. Waszut U, Szyszka P, Dworakowska D. Understanding mitotane mode of action. J Physiol Pharmacol 2017; 68: 13–26.
15. Megerle F, Kroiss M, Hahner S, et al. Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?. Exp Clin Endocrinol Diabetes 2018; 127: 109–116. https://doi.org/10.1055/a-0715-1946
16. Puglisi S, Calabrese A, Basile V, et al. New perspectives for mitotane treatment of adrenocortical carcinoma. Best Pract Res Clin Endocrinol & Metab 2020; 101415.
17. Tang Y, Liu Z, Zou Z, et al. Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis. Biomed Res Int 2018; 9362108. https://doi.org/10.1155/2018/9362108
18. Fassnacht M, Terzolo M,  Allolio B, et al. FIRM-ACT Study Group, Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366: 189-197.
19. Abraham J, Bakke S, Rutt A, et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002; 94: 2333-2343.
20. Le Tourneau C, Hoimes C, Zarwan C, et al. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: Phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer 2018; 6: 111.
21. Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: A large prospective phase II trial. Endocr Relat Cancer 2005; 12: 657-666.
22. Bukowski RM, Wolfe M, Levine HS, et al. Phase II Trial of Mitotane and Cisplatin in Patients With Adrenal Carcinoma: A Southwest Oncology Group Study. J Clin Oncol 1993; 11: 161-165.
23. Williamson SK, Lew D, Miller GJ, et al. Phase II Evaluation of Cisplatin and Etoposide Followed by Mitotane at Disease Progression in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma: a Southwest Oncology Group Study. Cancer 2000; 88: 1159-1165.
24. Gold B, Brunk G. A mechanistic study of the metabolism of 1,1-dichloro-2,2-bis(p-chlorophenyl)ethane (DDD) to 2,2-bis(p-chlorophenyl)acetic acid (DDA). Biochem Pharmacol 1984; 33: 979–982. https://doi.org/10.1016/0006-2952(84)90503-3
25. Doghman M, Lalli E. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma. Mol Cell Endocrinol 2013; 381: 66–69. https://doi.org/10.1016/j.mce.2013.07.023
26. Moolenaar AJ, van Slooten H, van Seters AP, et al. Blood Levels of o,p′-DDD Following Administration in Various Vehicles After a Single Dose and During Long-term Treatment. Cancer Chemother Pharmacol 1981; 7: 51–54. https://doi.org/10.1007/bf00258213
27. D’Avolio A, De Francia S, Basile V, et al. Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. Pharmacogenet Genomics 2013; 23: 293–300. https://doi.org/10.1097/FPC.0b013e3283606cb2